3D bioprinted beta cells can be used in
research and development of new drugs
for diabetes. They can also be used for
transplantation studies and reduce the
need for animal testing. For these reasons
we evaluated the PAN X bioink in beta cells.
The aim of following project was to culture and evaluate the viability of iPS derived beta cells, 3D bioprinted in CELLINK PAN X bioink.
The human pancreas has two main functions, an exocrine for digestion and an endocrine for regulating blood sugar levels. A precise regulation of blood sugar levels is necessary for key organs including the brain, liver, and kidneys to function correctly.
To use iPS derived beta cells have a number of advantages over using human islets. It can potentially serve as an unlimited source of starting material for a cell therapy product for the treatment of type 1 diabetes, as well as for drug testing and research. It can also abolish the need for islet donors (that are in shortage) and donor to donor variations.
The image beside show iPS derived beta cells in 2D culture before detachment and print.
Beta cells were mixed with PAN X bioink at a concentration of 30×106 cells/ml bioink. Using the BIO X, 2 µl droplets were printed in 96-well plates. The printing speed was 10 mm/s and the printing pressure was 8-10 kPa using 0,410 mm/22G conical nozzles.
The analysed viability numbers were 82% day 1 and 76% day 7 after printing. The image beside display the cell viability where the green represent living cells and the red dead cells. The high viability indicate that the cells survive well in the PAN X bioink and that the beta cell constructs can be used for further testing.
PAN X support viable beta cells for 7 days after print. The next step is to test the functionality of the cells in the islets printed in PAN X using a glucose stimulated insulin secretion assay.